COMPUTATIONAL DRUG DISCOVERY - NATURAL LANGUAGE PROCESSING - MACHINE LEARNING
Patient Responder Prediction for Clinical Trials
Drug Repositioning / Indication Expansion
Novel Target Identification & Prioritization
Pathway Analysis & Novel Pathway Discovery
Virual Drug Phenotypic Screening
Target Binding Site Prediction
Safety & Toxicity Analysis
Bioinformatics & Cheminformatics
API Access to BioXplor's Knowledgebase
BioXplor is offering data-driven discovery services to industry, academic, clinical and government laboratories involved in COVID-19 R&D, as well as other teams looking to accelerate or maintain their ongoing programs during the pandemic. BioXplor has a very experienced inhouse team as an extended team of trusted partners. Our clients include leading pharma companies such as Novartis, Bayer and Merck, as well as smaller biotechs and academic groups.
Data-Driven Discovery Services
Cloud-Based Platform Integration
Project Feasibility Form
Data-Driven Drug Discovery
BioXplor was founded in January 2017 and is backed by UC Berkeley Skydeck, Merck & European Innovation Council (Horizon 2020) accelerators, amongst other investment partners. The 10 person strong team has combined expertise in computer science and biomedical science applied to drug discovery, which are the core components of what we do, in equal measure. We are passionate about developing data-driven approaches to accelerate and improve Life Science R&D.
At BioXplor we are building an integrated CompBio platform to accelerate discoveries and reduce failures in drug discovery.
The integrated discovery platform works by generating obvious and non-obvious knowledge on a topic from structured and unstructured data using proprietary natural language processing and machine learning algorithms.
Our next stage is validating predictions in vitro via engineered disease models, patient data and bio-activity screening for drug discovery.
We have successfully applied the platform for Indication Expansion, Drug Repositioning, Pathway Analysis, Target ID, and Clinical Trial Responder ID, with clients including top 5 pharma and biotech companies.
BioXplor’s technology is available for licensing and we operate a CRO model.